共 50 条
Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
被引:14
|作者:
Saleki, Kiarash
[1
,2
,3
,4
]
Shirzad, Moein
[1
,2
,4
]
Javanian, Mostafa
[5
]
Mohammadkhani, Sheyda
[2
]
Alijani, Mohammad Hossein
[2
]
Miri, Niloufarsadat
[1
]
Oladnabi, Morteza
[6
]
Azadmehr, Abbas
[1
,4
,7
]
机构:
[1] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran
[2] Babol Univ Med Sci, Student Res Comm, Babol, Iran
[3] Babol Univ Med Sci, USERN Off, Babol, Iran
[4] Natl Elite Fdn, Mazandaran Prov Branch, Mazandaran, Iran
[5] Babol Univ Med Sci, Hlth Res Inst, Infect Dis & Trop Med Res Ctr, Babol, Iran
[6] Golestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
[7] Babol Univ Med Sci, Immunol Dept, Babol, Iran
来源:
关键词:
COVID-19;
hyperinflammation;
Fas;
viral Immunology;
immunoinformatics;
AA FORCE-FIELD;
EXPRESSION;
APOPTOSIS;
INJURY;
ACTIVATION;
VIRUS;
GENE;
D O I:
10.3389/fimmu.2022.947401
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients.
引用
收藏
页数:20
相关论文